Last $3.16 USD
Change Today +0.04 / 1.28%
Volume 96.0K
ADXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 2:36 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Snapshot

Open
$3.10
Previous Close
$3.12
Day High
$3.26
Day Low
$3.10
52 Week High
02/18/14 - $5.99
52 Week Low
04/15/14 - $2.46
Market Cap
61.7M
Average Volume 10 Days
163.7K
EPS TTM
$-1.15
Shares Outstanding
19.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVAXIS INC (ADXS)

Related News

No related news articles were found.

advaxis inc (ADXS) Related Businessweek News

No Related Businessweek News Found

advaxis inc (ADXS) Details

Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. The company’s Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. The company has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. Its products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA for the treatment of prostate cancer; and ADXS-cHER2 for the treatment of overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with human papillomavirus (HPV)-associated cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

17 Employees
Last Reported Date: 01/29/14
Founded in 2002

advaxis inc (ADXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $312.5K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $371.7K
Compensation as of Fiscal Year 2013.

advaxis inc (ADXS) Key Developments

Advaxis, Inc. Appoints David J. Mauro as Executive Vice President and Chief Medical Officer

Advaxis, Inc. announced that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs. In his role as Chief Medical Officer, Dr. Mauro will oversee the company's clinical immuno-oncology programs that utilize bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), to actively suppress key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack. Dr. Mauro most recently served as Executive Director, Section Head Oncology Clinical Development at Merck & Co., Inc. Dr. Mauro will oversee the company's clinical programs, including the planned Phase 3 clinical trial in cervical cancer, the Phase I/II study with ADXS-HPV in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer, and the Phase I/II study with ADXS-PSA in combination with Merck's approved PD-1 inhibitor, Keytruda, in metastatic, castration-resistant prostate cancer.

Advaxis, Inc. Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

Advaxis, Inc. announced preliminary data from its Phase 1/2 study of ADXS-HPV in human papillomavirus (HPV) associated anal cancer that indicate a 'clinical complete response' in all 7 patients who have completed the treatment regimen. Conducted by BrUOG, the Phase 1/2 trial is a non-randomized, open-label, multi-center study of 25 patients designed to determine the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer in patients who have a high risk of recurrence based on their disease. The primary efficacy objective of the study is to assess the proportion of patients maintaining a clinical complete response at the 6 month mark. Based on historical clinical experience in similar high risk patients and pursuant to the study protocol, the addition of ADXS-HPV will be considered promising if the 6 month complete response rate is greater than 80%. At present, 7 of 8 patients out of the planned total accrual of 25 patients have completed the treatment regimen. The 7 patients are without evidence of disease. Preliminary safety findings indicate flu-like symptoms were the most common adverse reaction lasting for about 24 hours. Patients have been treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). With these results, the study is being expanded to Ohio State University and Rutgers University, and these sites are in the process of activation.

Advaxis, Inc. Appoints Dr. Samir N. Khleif, as Board of Director

Advaxis, Inc. announced the appointment of world renowned oncologist and research scientist, Dr. Samir N. Khleif, to the company's Board of Directors. Dr. Khleif has more than 20 years of experience in the medical oncology, tumor immunology and immunotherapy fields. Dr. Khleif currently serves as the Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center and the Cancer Service Line. Dr. Khleif was formerly Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and also served as a Special Assistant to the Commissioner of the Food and Drug Administration (FDA) leading the Critical Path Initiative for oncology.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $3.16 USD +0.04

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eurocine Vaccines AB kr12.50 SEK +0.30
Genocea Biosciences Inc $9.04 USD +0.04
GenVec Inc $1.81 USD +0.03
Vical Inc $1.17 USD -0.04
ZIOPHARM Oncology Inc $3.04 USD +0.03
View Industry Companies
 

Industry Analysis

ADXS

Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit www.advaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.